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CHAPTER I 
INTRODUCTION 
Tumor immunology is presently one of the most promising areas 
of cancer research. The intrinsic qualities of the immune system 
suggest that it could be more effective in combating cancer than other 
methods which are now in use. First, it is the body's own natural 
defense mechanism, and second, it can reach all areas of the body. In 
instances of bacterial and viral invasion, the immune system of the 
host serves as an importaqt line of defense, and in almost all cases 
of treatment of disease, the immune system is responsible for the 
final clearing of the infective agents. 
The mechanisms utilized by the host in rejecting tumors is the 
same as those used in combating infection. The action of cell-mediated 
immunity can be demonstrated by (a) the adoptive transfer of lymphoid 
cells from an immune host to an infected host, or (b) by the in vitro 
mixing of sensitized lymphocytes and viable tumor cells. Antibody-
mediated immunity is thought to be mainly G-type immunoglobulins which 
are cytotoxic by binding of complement (Bellanti, 1971). 
Complexity is the rule in interactions between oncogenesis and 
immune reactions. It has, often been observed that there is an in-
creased incidence of tumors in pat~ents who have undergone immunosup-
pression for an organ graft (Hellstrom and Hellstrom, 1974). A 
popular explanation for this phenomenon is called immune surveillance. 
l 
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The different circulating components of the immune system are constant-
ly monitoring the internal environment in which it functions .. Marx 
(1974) suggests that neoplastic cells arise many times in the life of 
a complex organism but most are eliminated because of their foreign 
antigenic configuration. 
Another aspect of the complex reaction between tumor and host is 
that in response to a weakly antigenic tumor, different immune reac-
tions, which may or may or may not be effective, can be elicited. It 
has been observed that an early, weak immune response may be stim-
ulatory while a later, stronger response is inhibitory (Prehn, 1972). 
An alternate proposal to the immune surveillance theory is a 
theory supported by Marx (1974), which observes that close to half 
of all tumor types are associated with the lymphoreticular system, 
and that immunosuppression and immune deficiency diseases directly 
affect that system. Still, it is not clear how a developing tumor 
can escape detection by the immune system. 
Tumor immunology became feasable with the demonstration that 
most, if not all tumors possess antigens not characteristic of their 
tissue of origin. These antigens are known as tumor specific antigens 
(TSA) or tumor associated transplantation antigens (TATA). These 
antigens may or may not cross-react with antigens of other tumors of 
the same type. Probably all tumors caused by the same type of virus 
do cross-react, whereas most chemically-induced and spontaneous tumors 
cannot be demonstrated to have cross-reacting antigens (Old and Boyse, 
1964). 
One antigenic difference is known as a fetal antigen. Coggin 
(1974) states that an antigenic difference might result from renewed 
expressibn of genes normal to some previous stage of development. 
The presence of fetal antigens has been demonstrated by Ting(l972). 
Finely minced syngeneic fetal mouse tissue was injected intraperi-
toneally into inbred C3H/HeN male mice and their serum collected by 
retro-orbital bleeding. In a process similar to the indirect flu6r-
escent antibody technique, tumor cells were first incubated with the 
antiserum, then with 125r labeled antimouse gammaglobulin. The 
results were counted as positive when the radioactive count was more 
than double the count resulting from antisera produced from mice in-
jected with syngeneic adult tissue. The test serUJa must also not 
react with normal host cells. The results indicated the presence 
of antigens which were common to the fetal cells and the tum.or cells, 
and were recognized as foreign by the immune system of the host. 
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Viral antigens have also been shown to be expressed on some tumor 
cells. Roizman and Spear (1971) succeeded in using antiviral antibody 
to bind to cell surfaces and subsequently increase their density 
enough that they could be separated from unaltered membranes by cen-
trifugation on a sucrose density gradient. 
Three mechanisms have been suggested by Nowotny et al. (1974) 
by which a proliferating neoplasm can escape detection by the immune 
defenses of the host. First, the tumor cells might selectively lose 
their immunogenicity. Second, there could develop a growth enhancing 
immune response toward. the tumor, or third, an " interference" could 
occur to disrupt the anti-tumor effect developed by the host. Al-
though the third explanation is favored by their findings for their 
tumor-host system, other authors have found evidence to support the 
other two explanations too. The "interference" suggested by Nowotny 
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et al. (1974) was thought to be products of cell decay (PCD). Other 
authors such as Hellstrom and Hellstrom (1970) have suggested possible 
"serum blocking factors" that might be antigens which have been 
shed from the tumors and complex with antibodies in the medium. 
Prehn (1972) suggests a similar mechanism which is analagous to 
the situation of a pregnancy during which an antigenic configuration 
foreign to the host is present inside the body but is protected by the 
shedding of antigens, in this case, fetal antigens. 
Coggin and Anderson (1974) draw an analogy between the escape of 
a tumor and the escape of a fetus from immune rejection by the host. 
In both cases, the autochthonous lymphocytes have been shown to be 
cytotoxic to the respective cells, and sera from the pregnant and 
tumor-bearing hosts have been found to have blocking ability. They 
propose that the immune system of placental animals is poised to 
reject small numbers of cells exhibiting fetal antigens while allowing 
large masses of such cells to escape. 
With the demonstration of antigenic differences on tumor cell 
surfaces, it became clear they could be used as immunizing agents or 
immunotherapeutic agents after being inactivated. The modified cells 
can be used alone as an immunizing agent or in conjunction with chem-
otherapy, radiation therapy, or surgery as immunotherapy. 
A number of agents have been used to alter cells such as X-irrad-
iation at doses sufficient to kill the cells (Kolsch et al. 1973), 
Vibrio cholera neuraminidase which cleaves sialic residues from the 
membrane surface (Kollmorgen et al., 1973), iodoac~tamide which blocks 
sulfhydral groups, and mitomycin C, an inhibitor of DNA synthesis 
which may or may not lead to membrane alterations (Prager et al.,1974). 
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Prager et al. (1974) managed to achieve 80% survival of host organisms 
against a challenge of 1 X 103 tumor cells after vaccination with 
cells treated with iodoacetainide or mitomycin C. Kollmorgen et al. 
(1973) also achieved up to 80% success using neuraminidase treated 
cells after using chemotherapy to reduce the tumor burden to 1 X 105 · 
or fewer cells. 
Cell surface phenomena seem to account for many of the character-
istics observed in a developing tumor. The process of transformation 
changes the extent of cell to cell interactions which account for the 
change in social behavior and meta~tases (Coggin and Anderson, 1974). 
Even though internal cellular membranes may present antigens 
similar to the external ones~ it is clear that it is the plasma 
membrane of the tumor cell which primarily comes in contact with the 
immune surveillance system of the host. The plasma membrane is also 
thought to play an important role in processes such as cohesiveness 
and contact inhibition. 
It was because of these facts that experiments in this study were 
designed in which tumor cell plasma membranes were used to immunize 
animals against a subsequent administration of live tumor cells. 
The hypothesis was that isolated membranes would present more of 
the biologically important antigens per unit of material than altered 
whole cells. and that better results could be achieved using immuni-
zation schemes similar to others used with whole cells. 
CHAPTER II 
MATERIALS AND METHODS 
Tumor-Host System 
The animal hosts used in this study were female white mice of an 
outbred strain designated HaM/ICR, obtained from the Charles Rivers 
Mouse Farms, Wilmington, Mass. They were always isolated for two 
weeks when received in this laboratory, and given food and chlorinated 
water ad libitum to check for disease and parasites. At the initi-
ation of any experiment, the subject mice were at legst six weeks of 
age and had obtained a weight of at least 25 grams. 
In one experiment, the animal hosts were black female BDF1 mice 
obtained from Sprague-Dawley Laboratory, Madison, Wisconsin, and used 
at an age of about six weeks and a weight of about 20 grams. The BDF1 
is an inbred strain. 
The tumor cell line was Sarcoma 180. This tumor originated as a 
carcinoma in the axilla of an undesignated strain of white mouse. It 
was isolated in the Cancer Institute of Columbia University in 1914 
(Stewart et al., 1959). It was originally grown as a solid tumor but 
has been adapted to grow as an ascites cell, and the conversion 
occurred sometime before 1919. It is carried in this laboratory by 
weekly intraperitoneal transfers of about 1 X 106 cells diluted in 
cold Hepes buffered saline. 
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The tumor apparently shows fewer histocompatability antigens than 
an unaltered cell because of its ability to grow in different strains 
of mice. This fact is of primary importance because the histocompat-
ibili ty antigens are usually the most strongly expressed antigens. 
Their absence allows more detailed examination of reactions with tumor 
associated and fetal antigens. 
Tumor Cell Membrane Isolation 
The agent used as an immune stimulus in these experiments was 
tumor cell plasma membranes isolated by a procedure originated by Shin 
and Carraway (1973), using a modification of the Warren method (1969) 
of isolating membranes. 
The method consists of removing the ascites Sarcoma 180 cells 
from freshly killed mice, washing four times in cold Hepes buffered 
saline at pH 7.2, and centrifuging at 210 X g for three min. The 
supernatant solution, which contained ascites fluid and erythrocytes, 
was discarded. The pellet was suspended in 10 volumes of 40 mM Tris 
buffer at pH 7.4, and allowed to stand for three min to swell the 
cells. At the end of the designated time, the pellet was centrifuged 
at 1200 X g for two min. The supernatant solution containing hemo-
globin and some erythrocytes was also discarded. The pellet of about 
3 ml volume of swollen cells was suspended in 15 ml of 40 mM Tris 
buffer containing 1.0 mM MgC1 2 or ZnC12 and allowed to stand at room 
temperature for 15 min and then at 4 C for 15 min in order to "'harden" 
the cell membranes. The cell suspension was then tr~ated in a Dounce 
hand homogenizer with a loose pestle until microscopic examination 
r·eveaJ ed that about half the cells had been broken. An equal volume 
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of 40 mM Tris buffer was added, and treated with a slow centrifugation 
of 210 X g for three min to spin down nuclei and whole cells. The 
membranes in the supernatant were centrifuged at 1200 X g for 10 min 
for ZnC12 treated fractions or 2400 X g for 10 min for the MgCl2 
treated fraction. T.he supernatant solution which contains soluble 
cytoplasmic constituents was discarded. This separation yielded a 
supernatant solution which contained some mitochondria and a pellet 
that was rich in plasma membranes. T.he pellet was resuspended in Tris 
and layered onto a discontinuous sucrose density gradient, with layers 
of 8 ml each of 40%, 45%, 50%, and 55%.sucrose for the ZnC12 treated 
membranes, or 35%, 40%, 45%, and 50% for MgC12 treated membranes, and 
centrifuged at 4.1 X 104 X g .for 1 hr, or the-. pellet of membranes can 
be purified by suspension in a two-phase mixture of Dextran T500 and 
Carbowax 6000 and centrifuged at 8000 X g for 15 min. Either procedure 
yielded a band of purified tumor cell plasma membrane.s. All membrane 
preparations were frozen untii used. 
Membrane Quantitation 
T.he amount of membrane material available for use as an antigen 
was determined by the Lowry protein assay (Lowry et al., 1951). T.he 
purity of the membranes was checked by chemical and enzyme marker 
assays using lactoperoxidase, NADH diaphorase and adenosine triphos-
phatase, and also by SDS acrylarnide electrophoresis (Shin and 
Carraway, 1973). 
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Erythrocyte Membrane Isolaticm 
A readily accessible membrane to be used as a non-tumor immune 
stimulus may be obtained from mouse or human erythrocytes. Whole 
citrated human blood was obtained from the Community Blood and Plasma 
Service in Birmingham, Alabama, and mouse blood was collected in 
Alsever's solution (Barta, 1974). 
Membranes were obtained by the method of Triplett, Wingate, and 
Carraway (1972). The whole blood was centrifuged at 14,500 X g for 
10 min in a Sorvall SS-34 rotor to separate the cells from the serum, 
and washed three times in 10 mM Tris buffer pH 7.4 with 0.15 mM NaCl. 
The layer of white cells on the surface of the pellet was removed 
after each wash. To effect lysis, the cells were suspended in 10 
volumes of Tris buffer containing no NaCl, and allowed to stand for 
10 min at 4 C, and centrifuged at 14,500 X g for 10 min. The hemo-
globin was removed by six washes using two to three volumes of Tris 
buffer each time. These membranes were also frozen until used. 
Indirect Fluorescent Antibody Test 
The humoral response of a host to a tumor or an immunization 
can be checked using antibodies conjugated with fluorescein, in a 
method similar to that used by MBller (1961). The indirect method 
uses either conjugated goat anti-rabbit immunoglobulin or conjugated 
rabbit anti-mouse immunoglobulin, obtained from Cappel Laboratories 
Inc., Downingtown, Pennsylvania, and Sylvana Laboratory, Millburn, 
New Jersey respectively. 
Whole Sarcoma 180 cells were obtained fresh from a host, washed 
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and centrifuged twice in cold Hepes buffered saline. The dilutions of 
antiserum to be tested were then added to the pellet and allowed to 
incubate at room temperature for 15 min. The reaction was stopped by 
washing twice in cold Hepes buffer after which the pellets were in-
cubated with a standard dilution of the proper fluorescein conjugated 
antiserum. The unbound serum was removed with three more washes in 
Hepes buffer and the pellet was suspended in 1 ml of buffer and ob-
served under 500X magnification with a special fluorescein isothio-
cyanate-specific filter system, and darkfield conditions. Control 
~ 
slides were made using either normal mouse serum o~".' non-tumor cells or 
both, instead of the test tumor cells and. the primary antiserum. 
Dose - Response Experiment 
In order to detect any improvedment in the survival capabilities 
of the host CD1 (HaM/ICR) mice as a result of immunization, it was 
first important to delineate the ordinary tumor-host interaction. 
Seven different groups of 15 mice each were administered doses of 
viable Sarcoma 180 tumor cells by intraperitoneal injection, and the 
survival time of each mouse was noted. The mean survival time for 
each group was determined. 
Immunization Experiments 
Immunizations with Tumor Cell Membranes 
In the first immunization experiment, four groups of five CD1 
females about six weeks old were established. Each group received 
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intraperitoneal injections three times per week for two weeks, with 
the protein dosage set at 0.4 mg per injection. The first group was 
given ZnC12 treated tumor cell membranes, the second group MgC12 
treated tumor cell membranes, the third group received human red 
blood cell membranes type O+, and the fourth group received 0.2 ml 
of physiological saline as a control system. On day 18 of the test, 
each mouse was given 1 X 106 viable tumor cells as a challenge. The 
sur·vival time of each of the animals was recorded. 
A second immunization experiment was designed modifying the para-
meters used in the first experiment. Five groups of five mice each 
were set up. The protein dose was increased, and the tumor challenge 
was decreased by a factor of 10. However, 0.8 mg of protein injected 
three times per week is very close to the dose which can cause immune 
paralysis and allow normal rate of tumor growth, that is, one mg three 
times per week as reported by Mitchison (1968). Therefore the first 
injection remained at 0.4 mg of protein, and 0.8 mg on five subsequent 
injections, and total were given twice per week for three weeks to 
allow the immune system to develop a full response before the chal-
lenge dose was given. 
In this experiment one group received ZnC12 treated tumor cell 
membranes, the second group received MgC12 treated membranes, the 
third group 1 X 106 viable fetal mouse cells grown in cell culture 
(LM cells), the fourth group mouse red blood cell membranes. and the 
fifth group was given 0.1 ml of Hepes buffered saline on each injec-
tion. The survival time of each mouse was recorded. 
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Test for Cross-Reacting Antigens 
Another experiment was designed to test human erythrocyte mcm-
branes of different blood groups for cross-reacting antigens wit11 
immunizing capabilities against Sarcoma 180. 
Four groups of five mice each were established. Three of the 
groups received human erythrocyte membranes, 0.8 mg of protein three 
times per week for two weeks. The first group was given type B+, 
the second type 0-, and the third group type A-. The fourth group 
served as the control and received 0.2 ml of physiological saline 
each injection. A challenge dose of 1 X 105 viable Sarcoma 180 cells 
was given each mouse on day 14 of the test. The time of death or 
each mouse was noted and recorded. 
Titration of Immune Response 
A study was designed to determine the immunocompetence of host 
mice which had been immunized with tumor cell membranes. All test 
mice were immunized with six injections of Sarcoma 180 membranes, 
0.4 mg of protein on the first dose and 0.8 mg on the succeeding five 
doses, administered twice per week for three weeks. Control mice 
were given 0.2 ml of Hepes buffered saline each time. Four groups of 
ten mice each were given ZnG12 treated tumor cell membranes, another 
four groups of ten each were given MgC12 treated membranes, and four 
groups of five each served as control animals, injected with 0.2 ml 
of Hepes buffered saline each time. On day 25 of the test, one group 
from the ZnC12 membrane category, one from the MgC12 membrane category, 
and one from the control category were challenged with 1 X 104 viable 
Sarcoma 180 cells. Other groups from each category were challenged 
with 1 X 105, 1 X 106, or 1 X 107 cells. The individual survival 
times were recorded, and group mean survival times calculated. 
Titration of Antigen 
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To accompany the previous titration of immune response, a titra-
tion of antigenic material was designed. Smaller doses of membrane 
material were given in an effort to determine the minimum protein 
concentration that could be given while still achieving maximal 
results. 
Five groups of 10 CD1 mice were set up with one group receiving 
0.25 ml of Hepes buffered saline each time. In reference to the 
schedule of one injection of 0.4 mg of protein, and five injections 
of 0.8 mg, a total of twice per week for three weeks 1 the four test 
groups were given either 1/2, 1/4, 1/8, or 1/16 of the standard doses 
of ZnC12 treated tumor cell membranes. Respectively, the 1/2 group 
received one injection of 0.2 mg and five injections of o.4 mg of 
membrane material, the 1/4 group received one 0.1 mg injection, and 
five 0.2 mg injections. The 1/8 group received one 0.05 mg injection, 
and five 0.1 mg injections, and the 1/16 group received one 0.025 mg 
injection, and five 0.05 mg injections. A viable challenge of l X 105 
Sarcoma 180 was given on day 23 of the test. Again the survival times 
of each mouse was recorded, and the group mean survival times cal-
culated. 
In an attempt to see if the methods used with the Sarcoma lCJO 
and CD1 tumor-host system were applicable to another system, the 
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standard regimen was applied to the inbred BDF1 strain of mouse. 
Sarcoma 180 tumor cell membranes isolated by ZnC12 treatment from 
cells grown in cn1· mice were used as the antigen for a group of 10 BDF1 
females at six weeks of age. They were given 0.4 mg protein on the 
first dose and 0.8 mg for the following five doses which were admin-
istered twice per week for three weeks. A group of four control mice 
received 0.2 ml of Hepes buffer each time. On day 24 of the test, 
each mouse received 1 X 105 viable Sarcoma 180 cells. The survival 
times were noted. 
Intramuscular Challenge 
To see if the immunity conferred by this immunization techniGl.ue 
was successful with a challenge at a site other than the peritoneal 
cavity, a mouse which had previously been shown to be immune, and a 
mouse with no previous treatment were both injected intramuscularly 
in the right rear leg with 1 X 104 viable Sarcoma 180 cells. After 
seven days, the mice were sacrificed, autopsied, and histological 
sections taken from the muscle to check for tumor growth and host 
reaction. 
CHAPTER III 
RESULTS 
Dose - Response Experiment 
The basic survival response of the CD1 host mouse to different 
SA 180 tumor cell inoculation densities was determined in the Dose -
Response Experiment. Figure 1 shows the survival time of each mouse, 
plotted as a function of per cent cumulative mortality versus time in 
hours after tumor injection, with the dotted line indicating the mean 
survival time for each group. 
For convenience in estimating the expected survival time or the 
effective inoculum, on which to base data interpretation, the log of 
the tumor cell inoculation is plotted as a function of the mean sur-
vival time of each inoculation group (Fig. 2). Even though no injec-
tion of smaller than 1 X 102 cells was administered, it appears that 
an injection of one viable SA 180 cell would cause death of the host. 
Seven days following tumor implantation, one mouse was sacrificed 
from each group, and the serum collected and heat inactivated. A 
fluorescent antibody test was done with a dilution of 1:100, and 
evaluated on a scale of 1--4. A control slide using normal serum 
was also made. The titer for each of the groups was the same, about 
+l, indicating that antibodies were present in the system of each of 
the mice, directed against the tumor, but the level was very low. 
The control slide showed no non-specific staining. 
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Immunization Experiments 
Immunizations with Tumor Cell Membranes 
The results of the first of the immunizations experiments (Fig. 3) 
is plotted as the per cent surviving in each group versus the time 
after tumor cell injection. Line (a) represents the conbination of 
the control groups which were immunized with physiological saline, 
human red blood cell membranes, or MgC12 treated SA 180 membranes. 
Line (b) represents the test group that received ZnC12 treated SA 180 
membranes. The mean survival times for each of the groups in hours 
were, control groups: saline--290. 9, human erytht·ocyte membranes--
336. 2, and test groups: MgC12 sarcoma membranes--292.1, and in the 
ZnC12 sarcoma membrane group for those animals that died, the mean 
survival time was 332.2. Note also that two of the five animals, or 
40% in the ZnC12 sarcoma membrane group survived the challenge. 
The results of the second immunization are presented in Figure 4. 
Line (a) represents the combined survivals of the control group which 
received LM cells, the control group which received CD1 mouse erythro-
cyte membranes, and the control group which received Hepes buffered 
saline. The mean survival times of those groups were 306.7, 304.7, 
and 298.2 hrs respectively. Line (b) represents the survival of the 
ZnC12 treated sarcoma membrane group. Line (c) repr~sents the survival 
of the MgC12 treated membrane group. Note that 60% or three of five 
mice were able to completely reject their tumor load in the ZnC1 2 
treated membrane group, and that 80%, or four of the five mice in the 
MgCl2 treated membrane group rejected their tumor challenge of 1 X 105 
viable sarcoma. The mean survival time of the ZnC12 treated membrane 
immunized mice that died was 372.3 hrs, but only one mouse of the 
MgC12 membrane group died which made that number insignificant. 
Test of Long-Term Immunity 
In order to prove that the survivors were actually immunized, 
and that the immunity lasted at least 30 days, each mouse from the 
first two immunization experiments was re-challenged with 1 X 105 
viable SA 180 cells on the thirtieth day following the initial tu_mor 
cell challenge. All mice tested were able to reject the challenge, 
whereas control mice given the same injection died within the expected 
time period. 
To test their long-term immunocompetence, mice which had been 
immunized with ZnCl2 or MgC1 2 treated SA 180 membranes, and had sur-
vived a challenge of live tumor cells were re-challenged. Mice were 
used from groups that had received their last immunizing injection 
six months, five months, or three months before this challenge of 
l X 105 viable SA 180 tumor cells. Four control mice were also in-
cluded which died within the expected time period, but again all of 
the test mice survived the challenge, and showed no tumor development. 
Test for Cross-Reacting Antigen 
The possibility of a cross-reacting antigen was noted with the 
results of the first tumor cell membrane experiment. Therefore in 
the cross-reacting antigen experiment, types B+, 0-, and A- hwnan 
erythrocyte membranes were tested for immunizing capabilities. De-
spite previous indications, no protective ability was seen since the 
survival times of all groups were similar to the coptrol (Table I). 
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Titration of Immune Response 
In order to evaluate the effectiveness of immunization with tumor 
cell membranes on the schedule of two injections per week for three 
weeks with one injection of 0.4 mg protein and five injections of 0.8 
mg protein, groups were organized which were injected with MgC12 treat-
ed tumor cell membranes, and others were injected with ZnC12 tumor cell 
membranes. The results in table II show the capabilities of these 
animals to reject tumor challenges between 1 X 104 and 1 X 107 viable 
SA 180. Figure 5 shaw's the same results with line (a) representing the 
per cent survival of each group immunized with MgC12 treated tumor cell 
membranes versus viable tumor challenge dose. 
Titration of Antigen 
The results of the antigen titration experiment are presented in 
Table III. The mean survival times of each of the groups are compara-
ble within statistical limits. Note that there was one mouse in both 
the 1/2 and the 1/4 group which were able to survive the tumor chal-
lenge. These values should be compared with the mean survival time 
and number of surviving mice achieved in the immune response exper-
iment with the group which was immunized with ZnC12 treated tumor cell 
membranes and challenged with 1 X 105 cells (Table II). That group 
received 0.4 mg of membrane protein on the first injection, and five 
injections of 0.8 mg of protein. 
BDF1 - SA 180 Trial System 
The results of this experiment which was designed to test the 
capability of initiating immunity in an inbred strain of mouse with 
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isolated plasma membranes, and to test the specificity of such an 
i:minune response, are shown in Table IV. Neither of the test groups 
showed any improvement in mean survival time over the control groups. 
Intramuscular Challenge 
An intramuscular challenge was undertaken in this experiment to 
demonstrate that an immune host could reject a tumor challenge given 
at a site other than the peritoneal cavity. An autopsy on day seven 
showed no trace of tumor in the muscle of the immune animal, and 
there was no evidence of enlargement of regional lymph nodes. However, 
in the control animal, tumor cells had infiltrated between the muscle 
fibers, and the regional lymph nodes were greatly enlarged. 
Figure 1. Cumulative Mortality of HaM/ICR (CD1 ) Mice Fol-
lowing Injection of Different Cell Concentra-
tions of SA 180 
Seven groups of 15 mice each were challenged with viable 
SA 180 at concentrations of 1 X 102 through 1 X io8 cells. 
The number of animals dead from each group plotted as the 
per cent cumulative mortality is shown as a function of time 
following the tumor challenge. 
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Figure 2. Tumor Cell Inoculation Concentration as a Function 
of the Host Mean Survival Time 
Data derived from the Dose - Response experiment in which 
each point plotted represents the mean survival time of a 
group of 15 mice. 
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Figure 3. Per Cent of Animals Surviving At Times Following 
Injection of 1 X 106 SA 180 cells in the First 
Tumor Cell Membrane Immunization. 
Group (a) received physiological saline, human eryth-
rocyte membranes, or MgC1 2 treated SA 180 membranes. Group 
(b) received ZnC12 treatea SA 180 membranes. Each immuniza-
tion category was made up of five mice. All animals were 
challenged with 1 X 106 viable SA 180 cells. 
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Figure 4. Per Cent of Animals Surviving At Times Following 
Injection of 1 X 105 SA 180 Cells in the Second 
Tumor Cell Membrane Immunization. 
Group (a) received mouse erythrocyte membranes, LM cells, 
or Hepes buffered saline. Group (b) received MgC1 2 treated 
SA 180 membranes. Group (c) received ZnC12 treated SA 180 
membranes. Each immunization category was made up of five 
mice. All animals were challenged with 1 X io5 viable SA 180. 
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Figure 5, Immune Titration. 
All animals in line (a) were immunized with MgCl~ treated 
SA 180 membranes. All animals in line (b) were immunized with 
ZnC12 treated SA 180 membranes. Tumor challenge is iisted on 
the x-axis. There were 40 mice in each of the tumor membrane 
immunized categories and 20 control mice, which gives a total 
of 100 mice. No control mice survived any tumor challenge. 
Animals are labeled "survivors" if they live for 30 days 
after tumor injection. 
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Mean Survival 
Time (hours) 
TABLE I 
MEAN SURVIVAL TIMES OF MICE IMMUNIZED 
WITH HUMAN ERYTHROCYTE MEMBRANES 
Immunizing Agent 
Physiological 
Saline Type B+ Type 0-
356.7 329.2 317.3 
Each animal was challenged with 1 X 105 viable SA 180 after 
the immunization procedure. 
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Type A-
358.8 
TITRATION 
IMMUNIZING 
AGENT 
ZnCl2 
treated 
SA 180 
Membranes 
MgCl2 
treated 
SA 180 
Membranes 
Hepes 
Control 
TABLE II 
OF MEMBRANE IMMUNIZATION BY C~LLENGING MICE WITH SA 180 
AT CONCENTRATIONS OF 10 THROUGH 107 
Number of Viable SA 180 Injected Per Mouse 
104 105 106 107 
%s MST %s MST %s MST %s MST 
80 364 80 385 50 315 0 296 
80 391 60 368 40 305 0 259 
0 355 0 323 0 265 0 240 
%S--Per cent of animals surviving 30 days following 
SA 180 challenge. 
MST--Mean survival time (hours) for those animals 
in each group which died. 
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TABLE III 
TITRATION OF ANTIGEN - MEMBRANE MATERIAL 
Amount of Immunization 
control 1/2* 1/4* 1/8* 1/16* 
MST 327.8 335.3 327.1 340.8 
%s 0 10 10 0 0 
*The fraction represents the portion of the schedule of one 
injection of 0.4 mg and five injections of 0.8 mg of ZnC12 treated 
SA 180 membranes that each mouse received. 
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TABLE IV 
BDF l IMMUNIZA'I'ION WITH SA 180 ZnCl2 TREATED MEMBRANES 
CHALLENGED WITH SA 180 OR WITH Ll210 
Challenge 
1 X 105 SA 180 1 x 105 Ll210 
Test Groupa 235.8 202.8 
Control Groupb 313.6 193.5 
aBoth test groups immunized with one injection of 0.4 mg 
and five injections of 0.8 mg of ZnC12 treated SA 180 membranes 
bcontrol groups received six injections of 0.2 ml of Hepes 
buffered saline. 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
The CD1 - SA 180 tumor - host system shows a similarity to the 
human tumor situation. The CD1 strain of mouse shows more relevance 
to a human population since it is an outbred strain. One disadvantage 
of using an outbred strain of mouse is that each individual responds 
differently to antigenic stimulation. There is also some possibility 
that during growth, a transplantable tumor expresses a slightly 
different antigenic configuration in each animal. 
The Sarcoma 180 being a tumor showing an apparently reduced 
number of histocompatibility antigens is one that allows more direct 
experimentation with tumor associated transplantation antigens be-
cause their effect is not masked by the more strongly expressed histo-
compabili ty antigens. 
In regard to the dose - response experiment, and by looking at 
the time needed for a ten-fold increase in cell number, the cell 
generation time can be determined as being about 9.4 hrs. Taking 
together the initial inoculum,.the cell generation time, and the cor-
responding host survival time, it was determined that tumor burden at 
time of .death is fairly constant regardless of inoculation size. The 
exact burden at time of death cannot be determined because of altered 
cell kinetics at higher cell densities. The dose - response experi-
ment is a guideline for determining the success of later experiments 
34 
35 
using immunization and challenges. The Fluorescent Antibody test per-
formed on day seven in the Dose - Response experiment demonstrates 
the development of a weak immune response in all hosts with a tumor 
load between 1 X 104 and 1 X 107 cells. HoYlever, such a response can-
not be termed effective since regression has not been observed in 
any normal host. 
In comparison of the first and second tumor cell membrane exper-
iments, the reasons for the increased number of survivors in groups 
immunized with ZnC12 and MgC12 treated membranes are evident. First, 
the protein dosage was increased from 2.4 mg to 4.4 mg. Secondly, the 
immune stimulation was ad.ministered over a period of three weeks, and 
thirdly, the tumor challenge was decreased by a factor of 10. 
In the first tumor membrane experiment, a 40% survival rate was 
achieved utilizing ZnC12 treated tumor cell membranes as an immunizing 
agent. In the second experiment, using altered parameters, a 60% sur-
vival rate was seen using ZnC12 treated tumor cell membranes, and an 
80% survival rate was seen using MgC12 treated tumor cell membranes. 
Obviously these results indicate that the isolated plasma membranes 
exhibit antigens accessible to the immune system of the host that are 
also present on a viable tumor cell surface. 
Also in the second tumor membrane experiment, whole viable LM 
cells were tested for possible exhibition of fetal antigens that might 
be present on SA 180 cells. The mean survival time of the group sug-
gested that no immunizing capabil,i ty was present. However, Coggin 
and Anderson (1974) stated that no immunization could be demonstrated 
with whole viable fetal cells, because the cells proceed to mature 
inside a host. Immunization can only be demonstrated by using 
X-irradiated fetal cells between 10 and 11 hrs of development after 
fertilization. 
Human erythrocyte membranes were tested for the possibility of 
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a cross-reacting antigen with Sarcoma 180 in the third experiment. 
Even though a lengthening of the survival time similar to animals 
immunized with ZnC12 treated tumor cell membranes was indicated by 
immunization with human red blood cell membranes type O+ in the first 
tumor membrane experiment, no success was seen in immunizing hosts 
against SA 180 with membrane types B+, 0-, and A-. Although type O+ 
was not retested, ve-ry little possibility remains th~t any cross-
reacting antigen is present on human erythrocyte membranes. However, 
the membranes used in the first experiment may have been biologically 
"different" enough to cause a non-specific stimulation of the irrunune 
system. 
'rhe titration of immune response experiment showed that with 
each challenge dose, animals immunized with ZnC12 treated tumor cell 
membranes were more capable of rejecting their tumor challenge, or 
were capable of a longer survival time (Table II). The results are 
consistent with the first experiment in which more survivors were 
achieved with ZnC12 treated membranes than with MgC12 treated mem-
branes. The results of the second experiment appear inconsistent with 
this conclusion, but the difference between the groups was only one 
animal out of five, and the immune titration experiment, using 10 mice 
per group probably presented a more reproducable result. 
Also evident from the results of the immune titration was the 
fact that mice which had received identical immunizations were more 
capable of rejecting or partially eliminating smaller tumor 
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challenge doses than large ones. 
rrhe antigen titration experiment was an attempt to achieve suc-
cessful immunizations using smaller doses of immunizing material than 
had previously been tried. The results indicate that the schedule 
which had been adopted beforehand was the best compromise between 
reliability and economy, that is, injecting ZnC12 treated tumor cell 
membranes with one injection of 0.4 mg protein and five injections of 
0.8 mg a total of twice per week for three weeks. A group which was 
immunized in such a manner in the immune titration demonstrated a 
survival rate of 80% against a challenge of 1 X 105 viable SA 180, 
whereas the next lower group in the antigen titration which received 
1/2 as much protein dosage of membranes on each injection achieved 
only a 10% survival rate. 
The next experiment was an attempt to immunize the inbred BDF1 
strain of mouse with ZnC12 treated tumor cell membranes and one grbup 
was challenged with 1 X 105 SA 180 and another group was challenged 
with 1 X 105 Ll210 cells. The challenge with SA 180 cells was an at-
tempt to check the immunization of an inbred strain of mouse against 
an allogeneic tumor, and the challenge with Ll210 was to check the 
specificity of the immune response which was elicited by injection 
with sarcoma membranes. 
However, there was no lengthening of survival time in the group 
challenged with Sarcoma 180, and also no lengthening of survival time 
in the group challenged with Ll210. Therefore any possible cross-
reactivity between the tumors was not evident since no immunity was 
demonstrated against SA 180. The reason for the lack of immuni-
zation was not immediately evident since the Sarcoma 180 tumor is not 
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strain specific and should have expressed as much antigenic "foreign-
ness" in the BDF1 host as in the CD1 host. It does seem possible 
however, that a tumor might express different antigens in response to 
each type of host that it grows in, and tbe fact that the membranes 
used in this experiment were isolated from cells grown in CD1 hosts 
might affect the outcome of the experiment. 
A tumor challenge at a site other than the peritoneal cavity 
such as .the intramuscular challenge experiment is important because of 
two reasons. First, the peritoneal cavity is the area in which the 
immunizing injections were administered, and successful rejection of a 
tumor at that sight might not mean the host is also capable of re-
jecting tumors from sites where immunization was not given, and sec-
ondly, the peritoneal cavity is an immunologically privileged site 
where macrophages and lymphocytes are in constant circulation. 
Therefore, the results of the intramuscular challenge is a 
direct indication of the ability of the host to reject a tumor at any 
site .. The autopsy of the control host showed enlarged regional lymph 
nodes and tumor infiltration of muscle tissue which indicated that the 
presence of the tumor had'been detected by the irrunune system, but the 
reaction did not stop tumor growth. The absence of any lymph node 
enlargement or presence of any tumor cells in the immune host in-
dicated that the animal mounted an effective immune response, and all 
tumor cells had been eliminated before the autopsy on day seven. 
The immunity conferred by the procedures mentioned above are prob-
ably of the long-term type since animals which survived an initial 
tumor challenge at the end of each experiment were re-challenged with 
1 X 105 viable SA 180 30 days after the first challenge. Also mice 
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were selected from previous experiments that had survived tumor chal-
lenges three months, five months, and six months before a final chal-
lenge of l X 105 SA 180. In every instance, each host was capable 
of rejecting the tumor challenge. 
In conclusion, it has been shown that plasma membranes isolated 
from Sarcoma 180 tumor cells by the method of Shin and Carraway (1973) 
can be administered to host CD1 (HaM/ICR) mice on schedules and quan-
tities to induce immunity against a viable tumor challenge. 
It has also been shown that neither non-tumor control membranes 
such as ones isolated from human or mouse erythrocytes nor whole viable 
LM cells induce any immunity when administered in a regimen identical 
to the one used for tumor cell membranes. 
Results also indicated a distinct and repeatable difference in 
the success achieved when immunizing animals with sarcoma membranes 
isolated using ZnCl2 compared with membranes isolated using MgC12 . 
In most instances ZnC12 treated membranes are superior for immunizing 
capacity, but a survival rate of 80% against an intraperitoneal tumor 
challenge of 1 X 105 SA 180 has been achieved using both types. 
Furthermore, the resulting immunity has been shown to be long-term 
type, lasting at least six months, and it has been shown to be effec-
tive against tumor challenges at sites other than the peritoneal 
cavity such as in a muscle. 
It seems plausible that isolated tumor cell membranes could be 
used in remission therapy of cancer patients. If after surgery, mem-
branes could be isolated from directly removed cells, or cultured cells 
they could be administered to the patient to induce immunity to elimin-
ate any remaining cells at the primary, or possible metastatic sites. 
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